Compare Bank of Nova Scotia (BNS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs GeneDx Holdings Corp — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $108.32B), while GeneDx Holdings Corp trades at $81.32 (market cap $2.44B). The key difference: Bank of Nova Scotia is far larger — about 44.4× GeneDx Holdings Corp's market cap, and Bank of Nova Scotia pays a 3.64% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BNS | WGS | |
|---|---|---|
Market Cap | $108.32B | $2.44B |
Sector | Financials | Technology |
52-Week High | $90.29 | $167.51 |
52-Week Low | $56.41 | $34.51 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $90.34, up 2.01% with a bullish technical outlook supported by moving averages. The bank has delivered three consecutive earnings beats, with Q2 2026 EPS expected at $1.53. Recent acquisition of MapleMark Bank and dividend increase to $1.14 demonstrate strategic growth initiatives. Valuation metrics show P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a compelling investment case with strong fundamentals and analyst support (52.63% buy ratings), though revenue growth has been modest and interest expenses remain elevated. The stock faces risks from economic uncertainty and credit quality concerns, but dividend stability and improving ROE to 11.87% provide downside protection. Upside potential exists if the bank maintains earnings momentum.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
